Our top pick for
Cronos Group Inc is a drug manufacturers-specialty & generic business based in the US. Cronos Group shares (CRON) are listed on the NASDAQ and all prices are listed in US Dollars. Cronos Group employs 631 staff and has a trailing 12-month revenue of around USD$37 million.
|52-week range||USD$4 - USD$15.83|
|50-day moving average||USD$11.4579|
|200-day moving average||USD$7.7071|
|Wall St. target price||N/A|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$0.287|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Valuing Cronos Group stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Cronos Group's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Cronos Group's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 37x. In other words, Cronos Group shares trade at around 37x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
|Revenue TTM||USD$37 million|
|Gross profit TTM||USD$-17,864,000|
|Return on assets TTM||-5.78%|
|Return on equity TTM||5.82%|
|Market capitalisation||USD$3.8 billion|
TTM: trailing 12 months
There are currently 25.9 million Cronos Group shares held short by investors – that's known as Cronos Group's "short interest". This figure is 0.6% down from 26.1 million last month.
There are a few different ways that this level of interest in shorting Cronos Group shares can be evaluated.
Cronos Group's "short interest ratio" (SIR) is the quantity of Cronos Group shares currently shorted divided by the average quantity of Cronos Group shares traded daily (recently around 9.0 million). Cronos Group's SIR currently stands at 2.87. In other words for every 100,000 Cronos Group shares traded daily on the market, roughly 2870 shares are currently held short.
However Cronos Group's short interest can also be evaluated against the total number of Cronos Group shares, or, against the total number of tradable Cronos Group shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Cronos Group's short interest could be expressed as 0.07% of the outstanding shares (for every 100,000 Cronos Group shares in existence, roughly 70 shares are currently held short) or 0.1387% of the tradable shares (for every 100,000 tradable Cronos Group shares, roughly 139 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Cronos Group.
Find out more about how you can short Cronos Group stock.
We're not expecting Cronos Group to pay a dividend over the next 12 months.
Over the last 12 months, Cronos Group's shares have ranged in value from as little as $4 up to $15.83. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Cronos Group's is 1.9902. This would suggest that Cronos Group's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Cronos Group Inc. operates as a cannabinoid company in the United States and internationally. It manufactures, markets, and distributes hemp-derived supplements and cosmetic products through ecommerce, retail, and hospitality partner channels. The company is also involved in the cultivation, manufacture, and marketing of cannabis and cannabis-derived products for the medical and adult-use markets. Its brand portfolio includes PEACE NATURALS, a global wellness platform; adult-use brands comprise COVE and Spinach; and hemp-derived CBD brands consists of Lord Jones and PEACE+. Cronos Group Inc. is based in Toronto, Canada.
Everything we know about the Achilles Therapeutics plc IPO, plus information on how to buy in.
Everything we know about the SEMrush Holdings Inc IPO, plus information on how to buy in.
Everything we know about the ChargePoint IPO, plus information on how to buy in.
Everything we know about the Kaltura Inc IPO, plus information on how to buy in.
Everything we know about the Rocket Lab IPO, plus information on how to buy in.
Everything we know about the Soho House IPO, plus information on how to buy in.
Everything we know about the VIZIO IPO, plus information on how to buy in.
Everything we know about the IDW Media Holdings Inc IPO, plus information on how to buy in.
Everything we know about the Karooooo Ltd IPO, plus information on how to buy in.
Everything we know about the Connect Biopharma Holdings Limited IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.